- Review
Emerging Opportunities for Serotypes of Botulinum Neurotoxins
- Zhongxing Peng Chen,
- J. Glenn Morris,
- Ramon L. Rodriguez,
- Aparna Wagle Shukla,
- John Tapia-Núñez and
- Michael S. Okun
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. Thes...

